Total Payments
$40,205
2024 Payments
$12,149
Companies
38
Transactions
223
Medicare Patients
15,218
Medicare Billing
$2.0M
Payment Breakdown by Category
Other$15,000 (37.3%)
Research$8,193 (20.4%)
Food & Beverage$6,359 (15.8%)
Education$6,000 (14.9%)
Travel$4,653 (11.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Long term medical supply or device loan | $15,000 | 1 | 37.3% |
| Unspecified | $8,193 | 2 | 20.4% |
| Food and Beverage | $6,359 | 195 | 15.8% |
| Education | $6,000 | 1 | 14.9% |
| Travel and Lodging | $4,653 | 24 | 11.6% |
Payments by Type
General
$32,012
221 transactions
Research
$8,193
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AngioDynamics, Inc. | $21,035 | 3 | $0 (2022) |
| Eli Lilly and Company | $9,847 | 19 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $4,111 | 56 | $0 (2024) |
| Celgene Corporation | $1,114 | 7 | $0 (2018) |
| AstraZeneca AB | $833.37 | 7 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $500.26 | 26 | $0 (2024) |
| Inari Medical, Inc. | $334.26 | 3 | $0 (2022) |
| Boston Scientific Corporation | $319.67 | 10 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $264.65 | 15 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $254.32 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,149 | 63 | Eli Lilly and Company ($9,847) |
| 2023 | $811.37 | 35 | Bayer Healthcare Pharmaceuticals Inc. ($112.24) |
| 2022 | $16,412 | 42 | AngioDynamics, Inc. ($15,000) |
| 2021 | $6,299 | 17 | AngioDynamics, Inc. ($6,035) |
| 2020 | $647.84 | 12 | Novartis Pharmaceuticals Corporation ($423.85) |
| 2019 | $324.33 | 8 | BIOTRONIK INC. ($115.37) |
| 2018 | $1,180 | 8 | Celgene Corporation ($1,114) |
| 2017 | $2,381 | 38 | Novartis Pharmaceuticals Corporation ($1,272) |
All Payment Transactions
223 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $12.03 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/11/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $23.12 | General |
| Category: Genetic Disease | ||||||
| 11/20/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: Cardiology | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $308.36 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $226.86 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $202.21 | General |
| 11/14/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $150.97 | General |
| 10/30/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: DIABETES | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $7,425.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 09/18/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $16.46 | General |
| Category: Heart Failure and Hypertension | ||||||
| 09/11/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $39.94 | General |
| Category: Cardiology | ||||||
| 09/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $10.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/28/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: DIABETES | ||||||
| 08/21/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: Genetic Disease | ||||||
| 08/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: Cardio-renal | ||||||
| 07/31/2024 | Philips North America LLC | (CM9) Amb Mon & Diag Und (Device) | Food and Beverage | Cash or cash equivalent | $31.42 | General |
| Category: Medical Device | ||||||
| 07/25/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: General - Therapies_IC | ||||||
| 07/10/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $26.47 | General |
| Category: Genetic Disease | ||||||
| 06/26/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/19/2024 | Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor (Device) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: Cardiac Arrhythmia Monitoring | ||||||
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $339.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $339.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $320.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $175.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $8,193 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 2,587 | 3,267 | $1.8M | $324,226 |
| 2022 | 37 | 4,168 | 5,523 | $2.2M | $569,763 |
| 2021 | 40 | 5,074 | 8,205 | $3.0M | $690,240 |
| 2020 | 25 | 3,389 | 4,375 | $2.0M | $400,694 |
Total Patients
15,218
Total Services
21,370
Medicare Billing
$2.0M
Procedure Codes
132
All Medicare Procedures & Services
132 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 123 | 245 | $366,876 | $86,111 | 23.5% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 371 | 371 | $522,160 | $56,392 | 10.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 342 | 518 | $207,200 | $49,522 | 23.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 296 | 298 | $182,169 | $40,538 | 22.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 282 | 336 | $95,760 | $22,167 | 23.1% |
| 36475 | Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | Office | 2023 | 13 | 16 | $57,072 | $13,925 | 24.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 155 | 156 | $34,632 | $7,840 | 22.6% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 263 | 265 | $31,535 | $7,684 | 24.4% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 43 | 48 | $28,608 | $7,004 | 24.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 57 | 57 | $30,210 | $6,173 | 20.4% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 32 | 128 | $20,800 | $4,348 | 20.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 31 | 31 | $19,251 | $4,344 | 22.6% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 15 | 15 | $51,555 | $3,169 | 6.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 248 | 259 | $11,655 | $2,692 | 23.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 42 | 43 | $26,703 | $2,333 | 8.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 28 | 28 | $9,996 | $2,134 | 21.4% |
| 78803 | Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | Office | 2023 | 18 | 18 | $27,000 | $1,454 | 5.4% |
| 93924 | Ultrasound of leg arteries at rest and after exercise | Office | 2023 | 11 | 11 | $5,522 | $1,275 | 23.1% |
| 78472 | Nuclear medicine study of heart pumping function by labeling red blood cells with measurement of internal blood volume ejected with every beat over multiple cycles | Office | 2023 | 14 | 18 | $12,240 | $1,063 | 8.7% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 51 | 54 | $4,104 | $900.48 | 21.9% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 14 | 33 | $3,135 | $703.25 | 22.4% |
| J1245 | Injection, dipyridamole, per 10 mg | Office | 2023 | 44 | 213 | $63,900 | $606.68 | 0.9% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 12 | 15 | $2,730 | $507.37 | 18.6% |
| 78496 | Nuclear medicine study of heart pumping function over single cycle | Office | 2023 | 14 | 18 | $2,700 | $382.92 | 14.2% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 16 | 18 | $1,458 | $353.43 | 24.2% |
About Dr. Julian Javier, MD
Dr. Julian Javier, MD is a Interventional Cardiology healthcare provider based in Naples, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013938331.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Julian Javier, MD has received a total of $40,205 in payments from pharmaceutical and medical device companies, with $12,149 received in 2024. These payments were reported across 223 transactions from 38 companies. The most common payment nature is "Long term medical supply or device loan" ($15,000).
As a Medicare-enrolled provider, Javier has provided services to 15,218 Medicare beneficiaries, totaling 21,370 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 132 distinct procedure/service records.
Ad
Practice Information
- Specialty Interventional Cardiology
- Location Naples, FL
- Active Since 07/21/2006
- Last Updated 12/18/2012
- Taxonomy Code 207RI0011X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1013938331
Products in Payments
- Auryon Laser System 100-120 Vac (Device) $21,035
- ENTRESTO (Drug) $1,687
- Ozanimod (Drug) $1,114
- FARXIGA (Drug) $882.98
- JARDIANCE (Drug) $351.64
- FLOWTRIEVER CATHETER, S (Device) $334.26
- LEQVIO (Drug) $329.81
- XARELTO (Drug) $264.65
- Kerendia (Drug) $254.32
- ONPATTRO (Drug) $221.32
- PRADAXA (Drug) $132.58
- CARTO 3 (Device) $123.35
- Repatha (Biological) $122.28
- JETSTREAM (Device) $112.11
- ELIQUIS (Drug) $101.38
- VYNDAQEL (Drug) $88.78
- (5091) Amb Mon & Diag Und (Device) $62.84
- WATCHMAN FLX (Device) $58.13
- LifeVest (Device) $58.12
- BRILINTA (Drug) $48.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Interventional Cardiology Doctors in Naples
Dr. Robert Cubeddu, Md, MD
Interventional Cardiology — Payments: $256,069
Interventional Cardiology $256,069
Dr. Luis Paz Rios, Md, MD
Interventional Cardiology — Payments: $18,816
Interventional Cardiology $18,816
Dr. Adam Frank, Md, MD
Interventional Cardiology — Payments: $8,435
Interventional Cardiology $8,435
Dr. Ronald Levine, M.d, M.D
Interventional Cardiology — Payments: $6,120
Interventional Cardiology $6,120
Dr. George Gamouras, Md Faac, MD FAAC
Interventional Cardiology — Payments: $4,918
Interventional Cardiology $4,918
Bishoy Abraham, Md, MD
Interventional Cardiology — Payments: $2,241
Interventional Cardiology $2,241